Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Digestive Neuroendocrine Tumor”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)UnknownNCT02457650
What this trial is testing

T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies

Who this might be right for
Bladder CarcinomaBreast CancerEsophagus Carcinoma+7 more
Shenzhen Second People's Hospital 36
Large-scale testing (Phase 3)Ended earlyNCT00227617
What this trial is testing

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

Who this might be right for
Gastrointestinal Carcinoid TumorIslet Cell TumorLung Cancer+2 more
University of California, San Francisco 36
Not applicableStudy completedNCT06358001
What this trial is testing

EchoTip AcuCore Post-Market Clinical Study

Who this might be right for
AdenocarcinomaNeuroendocrine TumorsHepatocellular Carcinoma+5 more
Cook Research Incorporated 183
Not applicableActive Not RecruitingNCT02293954
What this trial is testing

Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer

Who this might be right for
Breast CancerColon CancerExtrahepatic Bile Duct Cancer+9 more
City of Hope Medical Center 20
Early research (Phase 1)Study completedNCT01186601
What this trial is testing

Exploration of Tumor Accumulation of BAY94-9392 in Patients With Cancer

Who this might be right for
Neoplasms
Lantheus Biosciences Ltd. 30
Testing effectiveness (Phase 2)Ended earlyNCT05714553
What this trial is testing

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

Who this might be right for
Advanced CancerAdvanced Solid TumorNeoplasm Malignant+14 more
NuCana plc 19
Early research (Phase 1)Ended earlyNCT05576077
What this trial is testing

TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors

Who this might be right for
Breast CancerColorectal CancerUveal Melanoma+3 more
Turnstone Biologics, Corp. 31
Testing effectiveness (Phase 2)Ended earlyNCT03361228
What this trial is testing

Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors

Who this might be right for
Solid Tumors
Incyte Corporation 5
Very early researchStudy completedNCT04752267
What this trial is testing

18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Glioma+17 more
University of Southern California 10
Early research (Phase 1)Study completedNCT00005860
What this trial is testing

Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum

Who this might be right for
Cancer
Memorial Sloan Kettering Cancer Center
Early research (Phase 1)UnknownNCT03634982
What this trial is testing

Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors

Who this might be right for
Solid Tumors
Revolution Medicines, Inc. 133
Not applicableUnknownNCT03033186
What this trial is testing

Everolimus TDM to Predict Long Term Toxicity

Who this might be right for
Breast CancerRenal Cell CarcinomaPancreatic Neuroendocrine Tumour+2 more
Maastricht University Medical Center 40
Testing effectiveness (Phase 2)Active Not RecruitingNCT02465060
What this trial is testing

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmBladder Carcinoma+49 more
National Cancer Institute (NCI) 6,452
Not applicableLooking for participantsNCT03740503
What this trial is testing

Genomic Investigation of Unusual Responders

Who this might be right for
CancerBreast CancerNon-small Cell Lung Cancer+8 more
University Health Network, Toronto 100
Not applicableStudy completedNCT05707286
What this trial is testing

Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy

Who this might be right for
MelanomaGastrointestinal NeoplasmsGenitourinary Cancer+2 more
Indiana University 98
Not applicableStudy completedNCT04761783
What this trial is testing

BESPOKE Study of ctDNA Guided Immunotherapy

Who this might be right for
Colorectal CancerMelanomaNon-small Cell Lung Cancer
Natera, Inc. 290
Early research (Phase 1)Study completedNCT00827177
What this trial is testing

Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) 87
Not applicableNo Longer AvailableNCT03554434
What this trial is testing

An Expanded Access Program for AM0010 (Pegilodecakin)

Who this might be right for
MelanomaProstate CancerOvarian Cancer+6 more
Eli Lilly and Company
Early research (Phase 1)Ended earlyNCT00739609
What this trial is testing

IDO Inhibitor Study for Relapsed or Refractory Solid Tumors

Who this might be right for
Breast CancerLung CancerMelanoma+2 more
NewLink Genetics Corporation 17
Early research (Phase 1)Active Not RecruitingNCT04521686
What this trial is testing

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Who this might be right for
CholangiocarcinomaChondrosarcomaGlioma+1 more
Eli Lilly and Company 200
Next Page